I agree wombat777. MSB has so many other disease indications available to it now that I would prefer to see future surplus capital (and there should be heaps of this before long) reinvested in speeding up approvals and new markets for the benefit of those with many other serious chronic inflammatory diseases. Also, shareholders would benefit more from this reinvestment than they would from any dividend. If there was to be a dividend, I would imagine it would not be much over 1% of profits - that would be easy to calculate from wombat777's figures.
I agree wombat777. MSB has so many other disease indications...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.10 |
Change
-0.025(2.22%) |
Mkt cap ! $1.261B | |||
| Open | High | Low | Value | Volume |
| $1.14 | $1.16 | $1.09 | $4.687M | 4.220M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 30 | 345852 | $1.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.10 | 58989 | 13 |
View Market Depth
| Last trade - 13.21pm 29/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |